← boardnext 2026-10
CLDX
Celldex Therapeuticsdistress 3/10 · well-funded / low risk$34.38-1%today-14% from 52w high
Oncology 1
Lead: Chronic Spontaneous Urticaria · target c-Kit
Revenue
pre-revenue
Liquidity
$451M
Runway
2.0 yrs
Shares 1y
+18%
Price & events
+28.1% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.1%
1D
-2.9%
1W
+4.3%
1M
+2.5%
3M
+32.7%
6M
+44.1%
1Y
-11.5%
2Y
-19.3%
5Y
+80.0%
All
Overview
- Market Cap
- $2.70B
- Volume
- 36.63K
- 52 Week Range
- $20.01 – $39.93
- Total Shares
- 78.49M
- Float Shares
- 72.46M
- Short %
- 11.70%
- % Held by Insiders
- 0.27%
- % Held by Institutions
- 95.89%
- RVOL
- 0.03x
- Beta
- 0.90
Pipeline stages · 2 programs
barzolvolimab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
CDX-585
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 7 trials · 4 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-10 Estimated 50% readout ~2026-12-15 | Phase 3 | barzolvolimab | Chronic Spontaneous Urticaria | — | active not recruiting |
| 2026-10 Estimated 50% readout ~2026-12-15 | Phase 3 | barzolvolimab | Chronic Spontaneous Urticaria | — | active not recruiting |
| 2028-06 Estimated 50% readout ~2028-08-15 | Phase 3 | Barzolvolimab | Chronic Inducible Urticaria, Cold Urticaria, Cold-Induced Urticaria, Symptomatic Dermographism | — | recruiting |
| 2028-09 Estimated 50% readout ~2028-11-15 | Phase 3 | barzolvolimab | Chronic Spontaneous Urticaria | — | enrolling by invitation |
| 2026-06 | Phase 2 | barzolvolimab | Prurigo Nodularis | 140 | active not recruiting |
Show all 7 trials · 2 more ▾
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2025-06-04 | Phase 2 | barzolvolimab | Eosinophilic Esophagitis | 86 | completed |
| 2025-05-21 | Phase 1 | CDX-585 | Non-small Cell Lung Cancer, Gastric Cancer, Head and Neck Cancer, Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Bladder Urothelial Carcinoma, Colorectal Cancer, Esophageal Cancer, Hepatic Cancer, Renal Cell Carcinoma, Cholangiocarcinoma, Pancreatic Cancer, Other Solid Tumors | 20 | completed |
Catalyst news & presentations · 2
- 2026-08-06Estimated 45%earningsEarningsEarnings releaseyahoo
- 2025-08-19trial discontinuedbarzolvolimab · Company will not advance barzolvolimab development in EoE following missed clinical endpoints.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $58 (+67% upside) · 15 analysts
- 2026-07-20GuggenheimBuy
- 2026-06-15HC Wainwright & Co.Buy
- 2026-06-10UBSBuy
- 2026-05-13Wells FargoOverweight
- 2026-05-08BarclaysOverweight
- 2026-04-20BarclaysUnderweight → Overweight
Competitors — c-Kit
- JSPRJasper Therapeutics, Inc.$21M · D3
Recent news
- 2026-07-22Celldex Therapeutics, Inc. (CLDX) Discusses Phase II Barzolvolimab Results in Prurigo Nodularis and Trial Discontinuation - Slideshow (NASDAQ:CLDX) 2026-07-22 - Seeking Alpha
- 2026-07-22Celldex Treatment Fails To Relieve Chronic Itch, Abandons Prurigo Nodularis Study - Benzinga
- 2026-07-22Morgan Stanley Adjusts PT on Celldex Therapeutics to $40 From $44, Maintains Overweight Rating - marketscreener.com
- 2026-07-21Celldex Reports Results from Phase 2 Study of Barzolvolimab in Prurigo Nodularis - GlobeNewswire
- 2026-07-20Guggenheim raises Celldex stock price target on trial outlook - Investing.com
- 2026-07-20Celldex Therapeutics (CLDX) PT Raised to $100 at Guggenheim - StreetInsider
- 2026-07-16Exclusive BAC Article: Celldex Therapeutics; Topline Phase 3 CSU Data Release Barzolvolimab Q4 2026, BLA Submission 2027, Expansions ColdU/SD Phase 3, Ph2 AD/PN 2026 Results And Catalysts (NASDAQ:CLDX) - Seeking Alpha
- 2026-07-15Celldex Therapeutics, Inc. Announces Retirement of Sam Martin from Senior Vice President, Effective on or About March 31, 2027 - marketscreener.com
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.